TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02755051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy for children with Chronic Insomnia and Autism Spectrum Disorder involves 8, one-hour sessions of a non-drug cognitive behavioral intervention. Session content listed below:~1. Sleep education~2. Sleep scheduling, limit setting, and stimulus control~3. Teaching relaxation strategies and other adaptive coping skills~4. Parenting strategies (differential attention, rewards, consequences)~5. Identification of maladaptive \& adaptive cognitions~6. Problem solving \& communication skills~7. Sleep restriction; bright light to change circadian rhythms~8. Review gains and plan for long-term maintenance
Study: NCT00965367

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acustimulation
Description: Acupressure in P6 bilaterally given after induction of anaesthesia for 20 minutes, followed by acupressure wrist bands applied on the same acupoints for 24 hours.

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Acustimulation
Description: Acupressure in P6 bilaterally given after induction of anaesthesia for 20 minutes, followed by acupressure wrist bands applied on the same acupoints for 24 hours.
Study: NCT03343327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronocort®
Description: Single dose of 20mg Chronocort® administered in one treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chronocort®
Description: Single dose of 20mg Chronocort® administered in one treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cortef®
Description: Single dose of 20mg Cortef® administered in one treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortef®
Description: Single dose of 20mg Cortef® administered in one treatment period
Study: NCT00291642

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drops
Description: * Pharmaceutical form: Drops for oral administration~* Route of administration: Oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets matching to levocetirizine
Description: * Pharmaceutical form: Tablets for oral administration~* Route of administration: Oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets matching to cetirizine
Description: * Pharmaceutical form: Tablets for oral administration~* Route of administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine drops
Description: * Pharmaceutical form: Drops for oral administration~* Concentration: 5 mg/ml~* Route of administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine tablets
Description: * Pharmaceutical form: Tablets for oral administration~* Concentration: 5 mg~* Route of administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine drops
Description: * Pharmaceutical form: Drops for oral administration~* Concentration: 10 mg/ml~* Route of administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine tablets
Description: * Pharmaceutical form: Tablets for oral administration~* Concentration: 10 mg~* Route of administration: Oral use
Study: NCT02802189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise programme
Description: Endurance and Resistant training exercise program (Duration: 45 minutes)~* Muscle retraining of longus colli and endurance training of the deep cervical flexors.~* Resistant exercises for the muscles involved in neck flexion, extension, side bending and rotation of the neck region. Isometric contractions exercises (20-70% of MVC) and resistant exercises (12-15RM).~* Active ROM exercises for the neck muscles~* Upper limbs exercises with resistant bands~* Stretching exercises for the neck and upper limbs muscles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise programme
Description: Endurance and Resistant training exercise program (Duration: 45 minutes)~* Muscle retraining of longus colli and endurance training of the deep cervical flexors.~* Resistant exercises for the muscles involved in neck flexion, extension, side bending and rotation of the neck region. Isometric contractions exercises (20-70% of MVC) and resistant exercises (12-15RM).~* Active ROM exercises for the neck muscles~* Upper limbs exercises with resistant bands~* Stretching exercises for the neck and upper limbs muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Neuromuscular Inhibition Technique application.
Description: Integrated Neuromuscular Inhibition Technique application.~(Duration: 15min)~The protocol was applied to the following muscles:~* Upper border of the trapezius muscle~* sternocleidomastoid~* levator scapulae muscle~* splenius capitis muscle~Integrated Neuromuscular Inhibition Technique includes the combination of the following technique:~* Ischemic compression~* Muscle energy technique~* Strain-counterstrain technique
Study: NCT01875289

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: obturator nerve block
Study: NCT01684410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-1 HC 200 mg
Description: Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 200 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
Study: NCT00997581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apremilast
Description: apremilast 20 mg taken twice daily by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: indomethacin SR
Description: indomethacin SR 75 mg taken twice daily by mouth
Study: NCT02371525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prepmate
Description: A novel multi-modal, technology-based intervention for pre-exposure prophylaxis (PrEP) adherence support .
Study: NCT01961908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Study: NCT00032162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 6 q4w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: 20/30/40 mg/qm q4w Dose finding study
Study: NCT03682952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil Injection
Description: Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost sodium tablets
Description: Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks ,then they take beraprost sodium tablets 40ug orally three times perday for 3 months.
Study: NCT02735746

Intervention type: RADIATION
Intervention: 4D Computed Tomography (CT)
Description: The initial 4DCT imaging obtained as part of a subject's planning CT for their standard radiation treatment.

Intervention type: RADIATION
Intervention: Cone Beam CT
Description: Daily cone beam CT imaging at each radiation treatment visit, as part of standard care

Intervention type: RADIATION
Intervention: Low-dose Cinefluorography
Description: A series of images consisting of five six-second cinefluorographs (real time fluoroscopic movies, for a total each time of 30 seconds of fluoroscopy) of the lungs while the subject is breathing, each at precisely measured angles to the subject, on 4 different occasions.

Intervention type: DEVICE
Intervention: Pulmonary Function Tests
Description: Pulmonary Function Testing (PFT) gives global functional data for the lungs as a whole, but is relatively insensitive to early pathological changes. It involves taking very deep breaths and exhaling as forcefully as possible.~Research PFTs will be conducted at 4 and 12-months post radiation therapy
Study: NCT00482547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogel Silver Salts Coated Latex Urinary Catheter System
Description: Silver-coated catheter

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bard silicone elastomer coated latex catheter system
Description: Silicone-coated catheter
Study: NCT02978326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217 15/20 mg Oral Solution
Description: SAGE-217, 15 mg oral solution, BID for Days 1 to 2 followed by 20 mg oral solution BID for Days 3 to 14. If not tolerated, 15 mg for the rest of study (Days 3 to 14).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAGE-217 matching placebo, capsules, orally, once daily, for up to 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE 217 30 mg Capsules
Description: SAGE-217, 30 mg, capsules, orally, once daily, for up to 14 days.
Study: NCT04229849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anrotenib plus Toripalimab
Description: Anrotenib: 10 mg on day 1-14 orally repeated every 21 days; Toripalimab: 240 mg on day 1 intravenously repeated every 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toripalimab
Description: Toripalimab: 240 mg on day 1 intravenously repeated every 21 days.
Study: NCT01225146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Ranibizumab is formulated as a sterile solution aseptically filled in a sterile 3-mL stoppered glass vial. Each vial contains 0.5 mL of 40 mg/mL (2.0-mg dose level) ranibizumab aqueous solution.
Study: NCT01875289

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: obturator nerve block
Study: NCT01392898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: liraglutide 1.8 mg q.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: insulin dosed according titration scheme
Study: NCT00617526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA806 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA806 1000 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA806 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA806 800 mg
Study: NCT01695070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 4mg prolonged release melatonin oral tablets twice daily
Study: NCT06487676

Intervention type: PROCEDURE
Intervention: Toe transfer
Description: Toe-to-hand transfer

Intervention type: PROCEDURE
Intervention: Replantation
Description: Finger or thumb replantation after amputation
Study: NCT01264224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028
Description: tablets, oral administration, single/multiple dosing, dose escalation
Study: NCT03478059

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive and Motor Dual-task Intervention
Description: The intervention will take place 3 times per week for 6 weeks (60 minutes/session) and employs motor and cognitive challenges. It is based on known motor and cognitive deficits after mTBI and is structured using a theoretical framework published in another domain of neurologic disease. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI. Each station will have 3 levels of difficulty with optional cognitive progressions. Subjects will spend 8 minutes at each station with a 2 minute transition/rest period between stations and will be progressed in motor and cognitive difficulty as able.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and Motor Dual-task Intervention
Description: The intervention will take place 3 times per week for 6 weeks (60 minutes/session) and employs motor and cognitive challenges. It is based on known motor and cognitive deficits after mTBI and is structured using a theoretical framework published in another domain of neurologic disease. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI. Each station will have 3 levels of difficulty with optional cognitive progressions. Subjects will spend 8 minutes at each station with a 2 minute transition/rest period between stations and will be progressed in motor and cognitive difficulty as able.
Study: NCT01491620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 532 nm KTP laser
Description: Laser treatment sessions on the neck and/or chest
Study: NCT04360811

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: COVID 19 diagnostic test by PCR
Description: 1. Inclusion of patients with clinical data (in a eCRF) and various samples collection according to the outcome of pregnancy~2. Storage and freezing samples for subsequent analysis by RT-PCR COVID-19 (maternal saliva, cord blood, fetal stools, placenta, fetal tissue, amniotic fluid according to pregnancy outcomes) and by maternal and newborn and / or fetal serologies testing~3. Pathological study of placentas and fetal autopsies~   * Histology of positive COVID-19 placentas~  * Brain and visceral histology of positive COVID-19 fetuses autopsied~4. Analysis of patient comorbidities and comparison in the different groups~5. Final statistical analysis

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: COVID 19 diagnostic test by PCR
Description: 1. Inclusion of patients with clinical data (in a eCRF) and various samples collection according to the outcome of pregnancy~2. Storage and freezing samples for subsequent analysis by RT-PCR COVID-19 (maternal saliva, cord blood, fetal stools, placenta, fetal tissue, amniotic fluid according to pregnancy outcomes) and by maternal and newborn and / or fetal serologies testing~3. Pathological study of placentas and fetal autopsies~   * Histology of positive COVID-19 placentas~  * Brain and visceral histology of positive COVID-19 fetuses autopsied~4. Analysis of patient comorbidities and comparison in the different groups~5. Final statistical analysis
Study: NCT00513968

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: a mixed plasmid DNA (HB-110)
Description: HB-110 2mg (or 4mg or 8mg), im, every other week, from week 0 to week 22 (total 12 injections) and Adefovir(Adefovir dipivoxil 10mg), od, from week -10 to from week 48.
Study: NCT01876459

Intervention type: OTHER
Group type: OTHER
Intervention: MRI

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Study: NCT03311906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.8% Hyaluronic Acid
Description: Application of 0.8% hyaluronic acid after scaling and root planing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Root Planing
Description: Scaling of the teeth using hand and ultrasonic scalers followed by planing of the root with curettes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing
Description: Scaling of the teeth using hand and ultrasonic scalers followed by planing of the root with curettes
Study: NCT03020368

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leeches

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Study: NCT02354118

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heparinized saline catheter flush
Description: The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline-only catheter flush
Description: The intervention group will have their port catheters flushed with saline only.
Study: NCT01331564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electronic intervention during pregnancy and postpartum
Description: Electronically-mediated behavioral interventions to encourage women to gain an appropriate amount of weight during pregnancy and to follow a healthy lifestyle postpartum to minimize postpartum weight retention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electronic intervention during pregnancy
Description: Electronically-mediated behavioral interventions to encourage women to gain an appropriate amount of weight during pregnancy.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control women will receive non-weight related content during both time periods at the project website.
Study: NCT04155801

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salix Probiotic Blend
Description: Oral capsule. The probiotic strains comprise the Salix Probiotic Blend include 3 strains of Bifidobacterium lactis (Bl-04®, Bi-07®, HN019) and 2 strains of lactobacillus (Lactobacillus acidophilus \[NCFM\]® and Lactobacillus paracasei \[Lpc-37\]®).
Study: NCT04152499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
Study: NCT01876459

Intervention type: PROCEDURE
Group type: OTHER
Intervention: lumbar puncture
Study: NCT04583501

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab will used as dose comparable to to 0.016 mg/kg/IU in serum.
Study: NCT03847402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The early integrated intervention for GDD
Description: The early integrated intervention for GDD integrates developmental approaches with strategies of applied behavior analysis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The early integrated intervention for ASD
Description: The theoretical underpinnings of the early integrated intervention for ASD originate from Early Start Denver Model.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The early integrated intervention for ADHD
Description: The methods of the early integrated intervention for ADHD includes behavior training, sensory integration training and psychological counseling
Study: NCT03847402

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: community intervention for ASD
Description: TEACCH (Treatment and Education of Autistic and related Communication- handicapped Children) intervention or ABA(applied behavior analysis) intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community intervention for GDD
Description: community intervention based on developmental approaches

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: community intervention for ADHD
Description: School and family education
Study: NCT03000153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Completing the Goals Form
Description: The Goals Form is a personalised outcome measure where clients enter their goals in collaboration with their assessor. Goals are then rated at the start of every session and open the therapeutic dialogue.
Study: NCT05645991

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coconut Sap Powder (CSP)
Description: CSP was given once daily (1.5 g/day) for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing aspartame (1.5 g/day) were taken orally once daily for 8 weeks.
Study: NCT01390506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium-selenite
Description: Di-sodium-selenite-pentahydrate (Na 2SeO3.5H2O) in 0,9% sodium chloride is administered intravenously at a does of 3000µg on day 0, 2000µg on day 1 and 2 and at a dose of 1000µg per day on day 3-6.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0,9% sodium chloride is administered intravenously
Study: NCT00385840

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine GSK1247446A
Description: Single dose, intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluarixTM
Description: Single dose, intramuscular injection
Study: NCT02721784

Intervention type: DEVICE
Group type: OTHER
Intervention: mpMRI/VERDICT
Description: Combined MRI sequences of T2, DCE, Diffusion and VERDICT

Intervention type: RADIATION
Group type: OTHER
Intervention: External Beam Radiotherapy
Description: 78Gy (Gray) to Prostate +/- Pelvic
Study: NCT01531426

Intervention type: DEVICE
Intervention: near infrared spectroscopy (INVOS®, Covidien)
Description: Measurement of regional cerebral oxygen saturation with non-invasive near-infrared INVOS® (In-Vivo Optical Spectroscopy) monitor by Covidien.
Study: NCT03665870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypoglycemia Education
Description: Two in-person visits to the home of the participant and 4 phone calls will be conducted to provided education on prevention of hypoglycemia.
Study: NCT04092478

Intervention type: OTHER
Intervention: Spinal Anesthesia Position
Description: The patient positions during the spinal anesthesia

Intervention type: OTHER
Intervention: Spinal Anesthesia Position
Description: The patient positions during the spinal anesthesia

Intervention type: OTHER
Intervention: Spinal Anesthesia Position
Description: The patient positions during the spinal anesthesia
Study: NCT03860155

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allo-APZ2-ACLF
Description: Administration of 2 x 10e6 allogeneic ABCB5-positive stem cells/kg bodyweight, each at Day 0, Day 5 (±1) and Day 13 (±1) into peripheral vein (arm) intravenously with a flow rate of 1-2 ml/min. Infusion of the product via a central venous catheter (CVC), a Port-a-Cath (Port) or a similar catheter is also possible. Allo-APZ2-ACLF will be in a concentration of 1 x 10e7 cells/mL in Human Serum Albumin/Ringer-Lactate/Glucose (HRG)-solution.